Format

Send to

Choose Destination
Pediatr Blood Cancer. 2012 Oct;59(4):736-8. doi: 10.1002/pbc.24003. Epub 2012 Jan 1.

Locoregional MYCN-amplified neuroblastoma.

Author information

1
Department of Pediatrics, University of Chicago, Chicago, Illinois 60637, USA.

Abstract

MYCN-amplification is strongly associated with other high-risk prognostic factors and poor outcome in neuroblastoma. Infrequently, amplification of MYCN has been identified in localized tumors with favorable biologic features. Outcome for these children is difficult to predict and optimal treatment strategies remain unclear. We report a 5-month-old who presented with an MYCN-amplified INSS stage 3, pelvic neuroblastoma. The tumor had favorable histology, hyperdiploidy, and lacked 1p36 and 11q23 aberrations. Although the patient met the criteria for high-risk neuroblastoma, because of the discordant prognostic markers we elected to treat her according to an intermediate-risk protocol. She remains event-free more than 18 months.

PMID:
22213566
DOI:
10.1002/pbc.24003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center